GlassScriptPhysician profile
Uday Shankar
NPI 1881660538
$64,480.09
in general payments reported to CMS, 2019-2025
42 companies · $40K in 2025
The $40K reported for 2025 was more than what 97% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $732 · 2020: $158 · 2021: $428 · 2022: $924 · 2023: $1,067 · 2024: $21K · 2025: $40K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $48K · Food and Beverage: $7,007 · Travel and Lodging: $4,344 · Consulting Fee: $2,414 · Education: $152.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $48,320.50 |
| Food and Beverage | $7,006.51 |
| Travel and Lodging | $4,344.46 |
| Consulting Fee | $2,413.50 |
| Education | $152.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $31,341.02 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $12,728.75 | 2025 | Rezdiffra |
| Takeda Pharmaceuticals U.S.A., INC. | $12,178.51 | 2019-2025 | Entyvio, Eohilia |
| Genzyme Corporation | $1,943.10 | 2022-2025 | |
| Abbvie INC. | $1,795.62 | 2019-2025 | Linzess, Creon, Viberzi |
| Janssen Biotech, INC. | $1,317.33 | 2021-2025 | Tremfya, Stelara, Simponi |
| Gilead Sciences, INC. | $307.61 | 2019-2025 | |
| Lilly USA, LLC | $304.59 | 2024-2025 | Omvoh, Zepbound |
| Janssen Scientific Affairs, LLC | $282.56 | 2019-2023 | Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $251.67 | 2019-2024 | Trulance, Xifaxan |
| Qol Medical, LLC | $235.68 | 2024-2025 | Sucraid, Sucraid |
| E.R. Squibb & Sons, L.L.C. | $201.28 | 2022-2023 | Zeposia |
| Novo Nordisk INC | $148.98 | 2025 | Wegovy |
| Teva Pharmaceuticals USA, INC. | $136.43 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $133.14 | 2023-2025 | Dupixent |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Uday Shankar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.